Login to Your Account



Taligen Gets $65M Series B for Complement Programs

By Trista Morrison


Monday, February 4, 2008
Taligen Therapeutics Inc. closed a tranched Series B financing round that eventually could bring the company as much as $65 million. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription